Table 1.
The comparisons of clinicopathological characteristics between the LVSI and non-LVSI groups, primary and validation cohorts
| Characteristics | LVSI
(+) (n = 151) |
LVSI
(-) (n = 82) |
p-value | Primary
cohort (n = 154) |
Validation
cohort (n = 79) |
p-value |
|---|---|---|---|---|---|---|
| Age, mean ± SD, years | 49.5 ± 10.1 | 50.9 ± 9.2 | 0.291 | 50.0 ± 9.3 | 49.9 ± 10.8 | 0.914 |
| MRI-reported LN status | 0.113 | 0.163 | ||||
| LN-positive | 56 (37.1%) | 22 (26.8%) | 52 (33.8%) | 26 (32.9%) | ||
| LN-negative | 95 (62.9%) | 60 (73.2%) | 102 (66.2%) | 53 (67.1%) | ||
| Tumor size (mm) | 39.5 ± 11.6 | 39.7 ± 11.4 | 0.888 | 39.8 ± 11.8 | 39.1 ± 10.9 | 0.707 |
| FIGO stage | 0.751 | 0.664 | ||||
| IB1 | 74 (49.0%) | 47 (57.3%) | 79 (51.3%) | 42 (53.2%) | ||
| IB2 | 27 (17.9%) | 12 (14.6%) | 26 (16.9%) | 13 (16.5%) | ||
| IIA1 | 34 (22.5%) | 16 (19.5%) | 35 (22.7%) | 15 (19.0%) | ||
| IIA2 | 15 (9.9%) | 7 (8.5%) | 14 (9.1%) | 8 (10.1%) | ||
| IIB | 1 (0.6%) | 0 (0%) | 0 (0%) | 1 (1.2%) | ||
| Histologic subtype | 0.312 | 0.211 | ||||
| Non-keratinizing SC | 57 (37.7%) | 37 (45.1%) | 56 (36.4%) | 38 (48.1%) | ||
| Keratinizing SC | 69 (45.7%) | 29 (35.4%) | 70 (45.5%) | 28 (35.4%) | ||
| Other subtypes | 25 (16.6%) | 16 (19.5%) | 28 (18.2%) | 13 (16.5%) | ||
| KI-67 | 0.107 | 0.211 | ||||
| ≥50% | 83 (55.0%) | 54 (65.9%) | 95 (61.7%) | 42 (53.2%) | ||
| <50% | 68 (45.0%) | 28 (34.1%) | 59 (38.3%) | 37 (46.8%) |
FIGO: 2009, International Federation of Gynecology and Obstetrics;LN: lymph node; LVSI: lymph-vascular space invasion; SC: squamous carcinoma.